Publications by authors named "Anna Sylwestrzak"
Objective: To compare the 52-week efficacy and safety of SB4 [an etanercept biosimilar] with reference etanercept (ETN) in patients with active RA.
Methods: In a phase 3, randomized, double-blind, multicentre study, patients with moderate to severe RA despite MTX treatment were randomized to receive 50 mg/week of s.c.
Objectives: SB4 (Benepali, Brenzys) is a biosimilar of reference etanercept (ETN). In a randomised, double-blind, 52-week study, SB4 demonstrated comparable efficacy and safety to ETN in patients with rheumatoid arthritis (RA). The open-label extension period evaluated long-term efficacy, safety and immunogenicity when continuing SB4 versus switching from ETN to SB4.
View Article and Find Full Text PDFArticle Synopsis
- - This study aimed to compare the effectiveness and safety of SB4, an etanercept biosimilar, with the original etanercept (ETN) in patients with moderate to severe rheumatoid arthritis who were not responding well to methotrexate therapy.
- - A total of 596 patients participated, receiving either SB4 or ETN for 24 weeks, with the main measure of success being a 20% improvement in disease symptoms (ACR20).
- - Results showed that SB4 and ETN had similar effectiveness and safety, with SB4 having a lower rate of antidrug antibodies, meaning it could be a suitable alternative to ETN for these patients.